Skip to main content
. 2019 Mar 4;10(3):219. doi: 10.1038/s41419-019-1436-1

Fig. 1. SAR131675 treatment decreases circulating monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-α (TNF-α) level in db/db mice.

Fig. 1

Circulating MCP-1 and TNF-α level were determined at 20 weeks in db/m and db/db mice treated with or without SAR131675. *P< 0.05 and #P< 0.001 vs. other groups